(S)-4-oxide-2,6-bisbis([1,1':3',1''-terphenyl]-5'-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin
- CAS NO.:1496637-09-2
- Empirical Formula: C56H45O4P
- Molecular Weight: 812.95
- Update Date: 2026-05-28 02:47:11
Properties of (S)-4-oxide-2,6-bisbis([1,1':3',1''-terphenyl]-5'-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin
| Density | 1.34±0.1 g/cm3(Predicted) |
| pka | 1.14±0.20(Predicted) |
Safety information for (S)-4-oxide-2,6-bisbis([1,1':3',1''-terphenyl]-5'-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin
| Signal word | Warning |
| Pictogram(s) |
![]() Exclamation Mark Irritant GHS07 |
| GHS Hazard Statements |
H315:Skin corrosion/irritation |
| Precautionary Statement Codes |
P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of soap and water. P332+P313:IF SKIN irritation occurs: Get medical advice/attention. |
Computed Descriptors for (S)-4-oxide-2,6-bisbis([1,1':3',1''-terphenyl]-5'-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin
New Products
2-(2-Chlorophenyl)glycine Propiolic Acid 1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene (±)-amino(2-fluorophenyl)acetic acid trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 1-Pentadecanol 2,4-Dihydroxybenzaldehyde Dipropyl disulfide Pyrrolo[1,2-a]pyrimidine-6-carboxylic acid, 4,6,7,8-tetrahydro-4-oxo-, sodium salt (1:1), (6S) Obidoxime hydrochloride API 4 pentyn 1 ol N-Vinylformamide Methacrylate-PEG-Methacrylate, Mn:35000 2,4-Dihydroxyacetophenone 2-Chloro 5-Fluoro Pyridine Vasicinone 2-Chloroisonicotinic Acid Tween 80 or Polysorbate 80 2-Butyn-1-oL N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine Pirtobrutinib intd. 2-Pentyn-1-oL 4-NitrobenzotrifluorideRelated products of tetrahydrofuran
![(11bR)-2,6-Bis([1,1'-biphenyl]-4-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin](https://img.chemicalbook.in/CAS/20210111/GIF/861909-35-5.gif)
![(11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis([1,1':3',1''-terphenyl]-5'-yl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin,99%e.e.](https://img.chemicalbook.in/CAS/20180703/GIF/1569807-15-3.gif)
![(R)-4-oxide-2,6-bis[4-(1,1-dimethylethyl)phenyl]-8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin](https://img.chemicalbook.in/CAS/20211123/GIF/1569807-27-7.gif)

![(11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[4-(trifluoromethyl)phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin](https://img.chemicalbook.in/CAS/20180703/GIF/791616-70-1.gif)
![(11bR)-2,6-bis[3,5-bis(1,1-diMethylethyl)-4-Methoxyphenyl]-4-hydroxy-4-oxide-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin](https://img.chemicalbook.in/CAS/20180808/GIF/957790-93-1.gif)

![(R)-4-oxide-2,6-bis[4-(4-methoxyphenyl)--8,9,10,11,12,13,14,15-octahydro-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin](https://img.chemicalbook.in/CAS/20211123/GIF/1011465-27-2.gif)
You may like
-
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
471-25-0 Propiolic Acid 98+View Details
471-25-0 -
84145-28-8 98+View Details
84145-28-8 -
trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 98+View Details
63909-29-5 -
2-(2-Chlorophenyl)glycine 88744-36-9 98+View Details
88744-36-9 -
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
629-76-5 98+View Details
629-76-5 -
1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene 98+View Details
39816-35-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

